论文部分内容阅读
目的探讨S100A6蛋白在甲状腺癌中检测的临床意义。方法免疫组化法检测110例患者甲状腺石蜡标本中S100A6蛋白的表达情况,其中甲状腺癌70例(乳头状癌48例、滤泡癌22例),甲状腺滤泡型腺瘤40例,正常甲状腺组织30例(对照),并对临床病理特征进行对比分析。结果 S100A6蛋白在甲状腺癌、腺瘤、正常甲状腺组织中阳性表达率分别为82.9%(58/70)、35.0%(14/40)、16.7%(5/30)。甲状腺癌组织与后两者比,S100A6蛋白的表达均有统计学意义(P<0.05)。有淋巴结转移的癌组织S100A6蛋白表达阳性率高于无淋巴结转移的癌组织(P<0.05)。结论 S100A6蛋白在甲状腺癌组织中过表达、与转移相关,可作为甲状腺癌重要的生物学指标,有希望成为一个能够预测甲状腺癌病情发展的标记物。
Objective To investigate the clinical significance of S100A6 protein in thyroid cancer. Methods Immunohistochemistry was used to detect the expression of S100A6 protein in thyroid specimens from 110 patients. There were 70 thyroid carcinomas (48 papillary carcinomas, 22 follicular carcinomas), 40 thyroid follicular adenomas, normal thyroid tissues 30 cases (control), and compare the clinical and pathological features. Results The positive rates of S100A6 protein in thyroid cancer, adenoma and normal thyroid tissue were 82.9% (58/70), 35.0% (14/40) and 16.7% (5/30), respectively. The expression of S100A6 protein in thyroid cancer tissues was significantly higher than that in the latter two groups (P <0.05). The positive rate of S100A6 protein expression in cancer with lymph node metastasis was higher than that without lymph node metastasis (P <0.05). Conclusion S100A6 protein is overexpressed in thyroid cancer and is associated with metastasis. It may serve as an important biological indicator of thyroid cancer and hopefully become a marker that can predict the progression of thyroid cancer.